NEW YORK – Stilla Technologies announced Tuesday it will partner with ID-Solutions, a French liquid biopsy firm, to commercialize oncology detection kits. Terms of the deal were not disclosed.
The commercialization partnership covers an oncology kit line the firms call Identify, which consist of a range of ready-to-use multiplexed mutation panels that run on the Stilla Naica digital PCR system.
Based in Grabels, France, ID-Solutions offers a line of oncology diagnostics that detect markers in circulating cell-free DNA from liquid biopsies and tumor DNA from solid biopsies.
The companies aim to offer standardized operating procedures and diagnostic tools to meet an urgent clinical need for highly sensitive and easy-to-use workflows in oncology applications, they said in a statement.
The partnership is also enabled by a new product line, called the Naica PCR Mix, which are dedicated digital PCR mastermix reagents including reagents for single assays and multiplexed PCR.
"We are very excited to add these new product lines to our portfolio," said Rémi Dangla, cofounder and CEO of Paris, France-based Stilla Technologies, noting that the mastermixes enable "robust application development on our platform." The Identify kit line is the first such solution for oncology applications, Dangla said, "demonstrating the power of our multiplexing approach to digital PCR."